Table 1 Patient characteristics
From: TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
No. of patients | 37 |
|---|---|
Age (years) | Â |
mean | 58 |
median | 61 |
range | 26-78 |
FIGO-Stage | Â |
I | 1 |
II | 1 |
III | 29 |
IV | 6 |
Histologic subtype | Â |
serous | 31 |
endometriod | 1 |
clear cell | 1 |
undifferentiated | 4 |
Grading | Â |
1 | 0 |
2 | 9 |
3 | 27 |
not determined/unknown | 1 |
Lymph node metastasis | Â |
pN0 | 11 |
pN1 | 18 |
NX | 8 |
Perioperative Ascites | Â |
<500 ml | 15 |
>500 ml | 21 |
not determined | 1 |
Residual tumor after surgery | Â |
microscopic | 22 |
macroscopic | 14 |
not determined | 1 |
Survival (months) | Â |
progression-free survival | Â |
mean | 20 |
median | 16 |
range | 2-71 |
overall survival | Â |
mean | 36 |
median | 32 |
range | 8-98 |